BioSpace News Archive

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications including ocular and urologic cancers, today announced that Elisabet de los Pinos, Chief Executive Officer of Aura, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx conference.

Outlook Therapeutics, Inc. announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,000,000 shares of common stock of Outlook Therapeutics, at a price to the public of $1.25 per share, less underwriting discounts and commissions.

Today, the U.S. Food and Drug Administration approved Livtencity (maribavir) as the first drug for treating adults and pediatric patients (12 years of age and older and weighing at least 35 kilograms) with post-transplant cytomegalovirus (CMV) infection/disease that does not respond (with or without genetic mutations that cause resistance) to available antiviral treatment for CMV.

Catalent, Inc., an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world.

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Jill Broadfoot to the company’s Board of Directors.

NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, will host a virtual tour of the Nanox.ARC at the RSNA Annual Meeting on December 1, 2021 at 11:30 am EST (10:30 am CST) as previously announced.

Paragon Consulting Partners, LLC today announces the launch of Strings by Paragon (Strings), a fully managed, vendor agnostic analytics solution for real-time enterprise imaging clinical workflow and applications monitoring.

Services in the global root canal market deal with elimination or minimization of bacteria from the infected root canal in a tooth.

Nykode Therapeutics announced that it has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialization of potential new vaccines for cancer and infectious diseases.

Tissue engineering refers to an interdisciplinary sphere that uses combination of life sciences and engineering.